Cumulus Neuroscience, a global digital health company, has published final results from its first-in-class CNS-102 study in Scientific Reports. The study was conducted in collaboration with the PRECISIONALS initiative, a Research Ireland academic–industry collaboration hosted by Trinity College Dublin. 

The paper, titled “Longitudinal cognitive assessment using the Cumulus NeuLogiq Platform in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,” demonstrates that the at-home NeuLogiq Platform was feasible, well tolerated and rated highly usable by people living with ALS and Frontotemporal Dementia (FTD) over an eight-month protocol.  

The ALS–Frontotemporal Spectrum Disorder (ALS–FTSD) field has long depended on clinic-based, primarily motor-focused endpoints — most notably the ALS Functional Rating Scale–Revised (ALSFRS-R) — to characterise disease progression. There is growing recognition that motor measures alone are insufficient to capture the cognitive, behavioural and physiological changes that define the disorder, and the field has called for richer, multimodal characterisation of patients in their everyday lives.  

The NeuLogiq Platform was designed to address that gap, combining a 16-channel wireless dry-sensor EEG headset with a tablet-delivered battery of gamified neurocognitive tasks spanning executive function, memory, language, social cognition and psychomotor speed. CNS-102 is the first published study to capture at-home EEG alongside a multi-domain cognitive battery in this patient population — a measurement combination that prior smartphone-, speech- and wearable-based remote platforms in ALS and FTD have not addressed.  

Peer-reviewed study and publication 

In the eight-month CNS-102 study, 28 participants (11 with ALS, seven with FTD and 10 healthy controls) completed in-clinic assessments every four months alongside home-based NeuLogiq assessments every two weeks. The platform achieved 92% data completeness across completed sessions and showed high usability, with ALS participants recording a mean System Usability Scale score of 89. 

NeuLogiq assessments distinguished ALS, FTD and control groups at baseline with effect sizes comparable to clinician-administered neuropsychological tests. Exploratory longitudinal analysis also identified potential changes in four measures, including speech fluency and emotion recognition in ALS, which were not detected by the less frequent in-clinic battery. The findings suggest that frequent, multimodal at-home assessment could provide more sensitive endpoints for neurodegenerative disease trials, although the small cohort means the results require validation in larger studies. 

The study was conducted with a consortium including Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK and Takeda, with a follow-up paper on the EEG findings planned.